Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1827
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV